Biotech and Pharmaceuticals Pharmaceuticals

More

  • Stocks got a boost from a better-than-expected report on the housing market, which overshadowed Caterpillar's gloomy outlook and other earnings worries.

  • Stock index futures pointed to a dip at the opening, despite a mega-deal brewing in the pharmaceutical sector.

  • Who's next in the potential wave of consolidation set off by Pfizer and Wyeth? Cramer has an idea.

  • Movement in a few key sectors could give stocks a much-needed boost.

  • Geron

    A few days into his term, President Obama appears to have begun to undo another Bush-era policy. He hasn't yet formally lifted the Bush-imposed ban on federal funding of new embryonic stem cell research, but Obama's Food and Drug Administration has already set the stage for it.

  • Ever wonder how these people decide which stock's a buy and which is a sell? Now you know.

  • Depends on which analyst you believe. Find out who Cramer's siding with.

  • real_medicine_rat.jpg

    For years pharmaceutical companies and health authorities have been trying to crack down on counterfeit prescription drugs. But on a new United Kingdom website the world's biggest drug company, Pfizer, is apparently taking the fight against knockoffs to a whole nutha level.

  • Dr. Steven Nissen

    Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.

  • 1st paragraph of story should go here

  • johnson_johnson2_logo.jpg

    Dow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson reported earnings this morning.

  • The JPMorgan Healthcare Conference typically frontloads the conference putting most, if not all, of the heavy hitters' presentations in the first couple of days of the four-day event. So, it's no surprise that a company the size of Dendreon was pulling up the rear. But that doesn't mean there wasn't any news.

  • Even though it's one of the leading causes of cancer death in the U.S., pancreatic normally doesn't get much attention.

  • Paul Noglows, director of research at Lazard Capital Markets, suggested four stock picks in four different sectors that will see growth over the year.

  • I couldn't go to the formal, scripted Genentech presentation at the JPMorgan Healthcare Conference yesterday afternoon because I was busy doing the crazy interview on "Fast Money" with the CEO of athenahealth, Jonathan Bush. I've never done a CEO interview like it.

  • Jamie Dimon

    During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."

  • Roche CFO's presentation at the JPMorgan Healthcare Conference

    Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference.

  • jp_morgan_front.jpg

    I'm covering the 27th Annual JPMorgan Healthcare Conference in San Francisco where I suspect there will be a big crowd for the Roche presentation later this morning. It's being reported that the Swiss drugmaker may soon raise its bid for Genentech. I'll be shocked if Roche says much about it either in the formal presentation or breakout session. But I'll be there just in case.

  • There's a method behind his Mad Money picks. Here's how you put that strategy to work yourself.

  • The FDA giveth and the FDA taketh away. Yesterday the agency handed Merck a little bit of a break with what could be interpreted as an endorsement, of sorts. But then this morning the FDA issued another delay in deciding whether to approve the company's Gardasil vaccine.